ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1152

Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1277

Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1024

Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry

(1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

9:00AM-11:00AM: Abstract Number: 1195

Relationship of Depth-Specific Subchondral Bone Mineral Density to MRI Cartilage Worsening: The Multicenter Osteoarthritis Study

(1183–1199) Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1313

Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1440

Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1519

Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis

(1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention

9:00AM-11:00AM: Abstract Number: 1356

Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis

(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1348

Reproductive Outcomes for Women with Vasculitis

(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1058

Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors

(1052–1081) Immunological Complications of Medical Therapy Poster

9:00AM-11:00AM: Abstract Number: 1475

Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1151

Revised IWOS Criteria for Ocular Sarcoidosis: A 2019 Review of the 2009 Criteria in a Study of 384 Patients from a Single University Hospital

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1014

Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities

(1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

9:00AM-11:00AM: Abstract Number: 0989

Rheumatoid Arthritis and Risk of Migraine: A Population-based Nationally Representative Cohort

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 0995

Rheumatoid Arthritis Early Diagnostic Clinic: A Web-based Referral Tool Serving Ethnic Minority Patients

(0993–1012) Health Services Research Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].